Sunday 18 October 2026 Export FULC’s income statement to Excel — free account

Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $80.0 million, up 2,752.0% from fiscal 2023. In the quarter to June 2026, EPS fell 21.4% and free cash flow fell 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.65 0.02 −0.54%

Follow FULC

Alert me

Market cap: $280.0M
P/E: 0.0×
Fwd P/E: −9.4×
Dividend yield: —
F-score: 5/9
Altman Z: 8.22
Beneish M: 21.24
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.49

Total sells 58.98

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	2	—	—	—
Sell	1	2	1	1	—	—	—	1	—	—	—	—

Insider Ownership 3.32%

Capital & Financial Ratios $m

Market Cap 280.01

Revenue 82.51

Net Income (85.00)

Free Cash Flow (65.69)

Net Debt (318.84)

Current Ratio 31.35

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (9.38)

P/S ratio 3.37

P/B ratio 0.90

Past 5Y EPS Growth —

This Y EPS Growth 48.94%

Next Y EPS Growth 79.78%

Next Y revenue growth (99.72%)

Next 5Y EPS Growth 63.32%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 11.82%

10-year low 10-year high

P/B against its own 10 years 13.54%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	236	241	352	319
Receivables	1	2	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	242	250	357	323

	2023	2024	2025	Q'26
Payables	3	1	2	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	14	11	13	10

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	61.02%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	29.67%	20.61%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’24	—	80	—	—	80
’23	0	1	1	1	3
’22	3	2	1	1	6
’21	5	4	5	5	19

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(16)	—	—	—
’25	(15)	(14)	(14)	(17)	(60)
’24	(25)	59	(19)	(17)	(2)
’23	(24)	(21)	(23)	(23)	(91)
’22	(22)	(27)	(28)	(20)	(97)
’21	(16)	(18)	(23)	(22)	(78)
’20	(15)	(14)	(5)	(20)	(54)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(16)	—	—	—
’25	(15)	(14)	(14)	(17)	(60)
’24	(25)	59	(19)	(17)	(2)
’23	(24)	(21)	(23)	(23)	(91)
’22	(22)	(29)	(28)	(20)	(99)
’21	(16)	(18)	(23)	(22)	(80)
’20	(16)	(14)	(5)	(20)	(55)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.25)	(0.34)	—	—	—
’25	(0.28)	(0.28)	(0.31)	(0.31)	(1.18)
’24	(0.43)	0.87	(0.35)	(0.31)	(0.16)
’23	(0.41)	(0.38)	(0.39)	(0.40)	(1.59)
’22	(0.64)	(0.83)	(0.51)	(0.50)	(2.44)
’21	(0.54)	(0.60)	(0.57)	(0.58)	(2.29)
’20	(0.81)	(0.66)	(0.70)	(0.64)	(2.79)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	4.37	7.01	6.85	3.21	2.25	2.86	2.32	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	19.30	22.96	33.10	24.79	15.00	13.70	15.74
People
People	Employees	—	—	62	73	73	104	89	76	45	55
	Revenue/emp, $m	—	—	0.00	0.00	0.12	0.18	0.07	0.04	1.78	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	9	19	6	3	80	—
	Gross margin, %	—	0.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00	—
	EBT	—	(23)	(33)	(83)	(71)	(81)	(110)	(97)	(10)	(75)
	EBT margin, %	—	0.00	0.00	0.00	(802.66)	(421.89)	(1,732.43)	(3,470.05)	(12.16)	0.00
	Net income	—	(23)	(33)	(83)	(71)	(81)	(110)	(97)	(10)	(75)
	Depreciation	—	1	1	2	2	3	2	2	2	1
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.35	0.54	0.14	0.05	1.29	0.00
	Earnings	—	(32.30)	(25.93)	(8.13)	(2.79)	(2.29)	(2.44)	(1.59)	(0.16)	(1.18)
	Cash flow	—	(28.23)	(17.95)	(3.57)	(2.12)	(2.22)	(2.16)	(1.48)	(0.04)	(0.95)
	Capex	—	(2.68)	(7.14)	(0.08)	(0.05)	(0.05)	(0.04)	(0.01)	0.00	0.00
	Free cash flow	—	(30.92)	(25.09)	(3.65)	(2.17)	(2.27)	(2.20)	(1.49)	(0.04)	(0.95)
	Book value	—	1.86	60.46	7.89	3.75	5.98	4.42	3.84	3.92	5.51
	Shares, m	—	1	1	11	25	35	45	61	62	63
Valuation, ×
Valuation, ×	P/E	—	—	—	—	0.00	0.00	0.00	0.00	0.00	—
	P/S	—	—	—	—	33.65	32.64	56.04	157.59	3.53	—
	P/B	—	—	—	—	3.12	2.96	1.79	1.88	1.20	—
	EV/Sales	—	—	—	—	20.85	21.26	24.05	73.38	0.61	—
	EV/FCF	—	—	—	—	(3.35)	(5.08)	(1.54)	(2.25)	(20.15)	—
Cash, $m
Cash, $m	Operating cash flow	—	(20)	(23)	(39)	(54)	(78)	(97)	(91)	(2)	(60)
	Capex	—	(2)	(9)	(1)	(1)	(2)	(2)	(1)	0	0
	Free cash flow	—	(22)	(32)	(40)	(55)	(80)	(99)	(91)	(2)	(60)
Balance, $m
Balance, $m	Working capital	—	(1)	70	88	93	207	191	229	239	344
	Total debt	—	35	140	0	0	—	13	—	—	—
	Net debt	—	0	(73)	(97)	(113)	(218)	(203)	(236)	(241)	(352)
	Shareholders’ equity	—	1	76	87	95	212	199	235	243	349
Returns, %
Returns, %	ROA	—	(56.31)	(86.89)	(91.54)	(59.01)	(44.35)	(47.60)	(40.19)	(3.75)	(23.89)
	ROIC	—	(1,570.56)	(653.65)	0.00	0.00	0.00	0.00	0.00	(679.86)	0.00
	ROE	—	52.35	80.77	(764.85)	(77.68)	(52.72)	(53.53)	(44.84)	(4.07)	(25.30)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Jun 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BNTC Benitec Biopharma Limited	$295.1M	— (loss-making)	— (loss-making)	−85.42% (below 0%: shrinking)	n/m	+38.90% (above 0%: growing)	0.00%	0.00%	Compare
SRZN Surrozen, Inc.	$294.7M	— (loss-making)	— (loss-making)	+408.65% (above 0%: growing)	n/m	−21.25% (below 0%: shrinking)	100.00%	(207.40%)	Compare
FULC Fulcrum Therapeutics, Inc.	$280.0M	— (loss-making)	— (loss-making)	+27,018.64% (above 0%: growing)	n/m	−13.05% (below 0%: shrinking)	100.00%	0.00%
OCGN Ocugen, Inc.	$275.9M	— (loss-making)	— (loss-making)	+8.38% (above 0%: growing)	n/m	−13.42% (below 0%: shrinking)	100.00%	(1,105.11%)	Compare
NAUT Nautilus Biotechnology, Inc.	$274.9M	— (loss-making)	—	—	n/m	−3.16% (below 0%: shrinking)	92.11%	(8,296.32%)	Compare
IPSC Century Therapeutics, Inc.	$271.6M	— (loss-making)	— (loss-making)	+12,667.72% (above 0%: growing)	n/m	+26.66% (above 0%: growing)	100.00%	0.00%	Compare
EYPT EyePoint, Inc.	$270.7M	— (loss-making)	— (loss-making)	−90.49% (below 0%: shrinking)	n/m	+0.41% (above 0%: growing)	100.00%	(19,207.10%)	Compare
PALI Palisade Bio, Inc.	$268.4M	2.2×	— (loss-making)	+19,900.00% (above 0%: growing)	n/m	−318.44% (below 0%: shrinking)	100.00%	(2,339.60%)	Compare
ABEO Abeona Therapeutics Inc.	$265.9M	— (loss-making)	— (loss-making)	+225.14% (above 0%: growing)	n/m	+17.11% (above 0%: growing)	63.30%	(119.97%)	Compare
Median of peers	$273.2M	—	—	+225.14%	—	−1.38%	100.00%	(656.25%)

All 614 Biotechnology stocks →

Fulcrum Therapeutics, Inc. (FULC) key facts

Strength: Fulcrum Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $80.0 million, up 2,752.0% from fiscal 2023.
Fulcrum Therapeutics, Inc. (FULC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, FULC traded at $3.65, a market capitalization of $280.0 million.
Return on equity was −25.3% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 8.22 (safe zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.